Syn-ake

Syn-ake partially inhibits the epsilon subunit of the nicotinic acetylcholine receptor at the dermal neuromuscular junction, mimicking the mechanism of waglerin-1. This partial blockade reduces the efficiency of acetylcholine transmission from motor neurons to facial muscles underlying the skin. The result is a mild reduction in facial muscle contraction in response to expression movements, reducing the mechanical forces on overlying skin that drive dynamic wrinkle formation over time.

Botulinum toxin cleaves SNAP-25 (a SNARE protein) irreversibly, preventing all acetylcholine vesicle fusion and causing complete, sustained muscle paralysis lasting 3-6 months. Syn-ake provides reversible, partial nAChR blockade with much weaker and shorter-lived effects, producing a fraction of the wrinkle-reducing effect. The comparison is a marketing framing, syn-ake is a cosmetic ingredient with modest effects, not a medical treatment.

Electrophysiology studies (DSM, in-house) show syn-ake inhibits nAChR with an IC50 approximately 1000-fold higher than waglerin-1, confirming weak partial agonism. In cultured muscle cells, syn-ake reduces acetylcholine-induced contraction amplitude. Whether these in vitro concentrations are achievable in skin at cosmetic formulation levels is debated.

A 4-week consumer study (n=45) using standardized skin surface analysis showed approximately 52% reduction in wrinkle depth in the crow's feet area compared to vehicle. Volunteer self-assessment showed high satisfaction ratings. These are cosmetic claims studies with inherent methodological limitations (small n, potential bias, subjective endpoints) and should not be interpreted as clinical trial evidence.